{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125444","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.753005+00:00","generated_at":"2026-05-30T01:51:34.530197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tempest reports Q3 net loss $10.6M; gets FDA go-ahead for amezalpat Phase 3 in first-line HCC","bullets":["Net loss of $10.6M ($0.41/sh) in Q3 2024 vs $6.8M ($0.48) in Q3 2023; cash $22.1M, then raised $19.9M net via ATM.","FDA issued 'Study May Proceed' letter for pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in first-line HCC.","Announced agreement with Roche to supply atezolizumab globally for the Phase 3 trial; Tempest retains all rights to amezalpat.","Positive end-of-Phase 2 FDA meeting: agreement on Phase 3 design, dose, statistical plan with early efficacy analysis.","Expanded leadership: Troy M. Wagner as VP Quality Assurance and Sheldon Mullins as VP Regulatory Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125444","json":"https://secwatch.observer/filing/0000950170-24-125444.json","markdown":"https://secwatch.observer/filing/0000950170-24-125444.md","text":"https://secwatch.observer/filing/0000950170-24-125444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024125444/0000950170-24-125444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024125444/tpst-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:51:34.530197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}